QUALIS PHARMA SOLUTIONS LIMITED

Company number 13666794 ·

Active

This analysis was written by an AI from the company's public filings. It may contain errors or omissions and is not financial or professional advice.

QUALIS PHARMA SOLUTIONS LIMITED - Analysis Report

Company Number: 13666794

Analysis Date: 2025-07-19 13:05 UTC

  1. Risk Rating: LOW
    The company demonstrates positive net current assets and net assets with a consistent increase year on year. There are no overdue filings, liquidation, or administration indicators, and the micro-entity status limits complexity and reporting risk.

  2. Key Concerns:

  • Absence of employees reported over multiple years may indicate heavy reliance on director or outsourced resources, potentially affecting operational scalability and resilience.
  • The company is very young (incorporated 2021), so it lacks a long financial history to fully assess stability and performance trends.
  • The financial statements are unaudited, which is typical for micro-entities but limits third-party assurance on reported figures.
  1. Positive Indicators:
  • Net current assets increased substantially from £6,657 in 2023 to £19,161 in 2024, indicating improving liquidity and working capital position.
  • Shareholders’ funds have grown in line with net assets, suggesting retained earnings or capital injections are strengthening equity.
  • All statutory filings (accounts and confirmation statements) are up to date with no overdue notices, indicating good regulatory compliance.
  • The sole director and 100% shareholder has been in place since incorporation, providing continuity of control.
  1. Due Diligence Notes:
  • Verify the source of the increased current assets and whether these are cash or receivables, to confirm liquidity quality.
  • Understand the business model and revenue generation given zero employees reported; assess sustainability and dependency on external contractors or director involvement.
  • Confirm absence of contingent liabilities or off-balance-sheet risks not disclosed in the micro-entity accounts.
  • Review any corporate governance policies or risk management practices given the sole director structure.
  • Assess the impact of no audit on financial statement reliability, particularly since the accounts are prepared under micro-entity rules.

Perspective: Investment Risk Assessor · Model: gpt-4.1-mini · Generated 19 July 2025

Sign in to generate a free AI analysis of this company — no password needed, just an email link.